ACTU
NASDAQActuate Therapeutics Inc.
Price$1.90-1.15 (-37.70%)
2026-03-042026-06-05
News · 26 weeks35+13%
2025-12-142026-06-07
Mix2590d
- Insider11(44%)
- SEC Filings9(36%)
- Other2(8%)
- Leadership2(8%)
- Market1(4%)
Latest news
25 items- PRActuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer- Patients with KRAS wild-type (WT) genomics achieved significant improvement in median overall survival (mOS) when treated with elraglusib plus gemcitabine/Abraxane (GnP) versus GnP alone - Patients with P53WT genomics receiving elraglusib plus GnP showed a near doubling of mOS versus GnP alone - Patients receiving elraglusib plus FOLFIRINOX demonstrated deep and sustained clinical responses and increased mOS versus FOLFIRINOX alone or in combination with losartan - Elraglusib treatment was well tolerated when used in combination with either GnP or FOLFIRINOX CHICAGO and FORT WORTH, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU), a clinical-stage bio
- SECActuate Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)
- INSIDERSEC Form 4 filed by Director Zabrowski Dan4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)
- INSIDERSEC Form 4 filed by Director Thomson Todd S4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)
- INSIDERSEC Form 4 filed by Director Sawhney Roger4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)
- INSIDERSEC Form 4 filed by Director Ronneberg Amy L4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)
- INSIDERSEC Form 4 filed by Director Keyes Jason A4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)
- INSIDERSEC Form 4 filed by Director Huber Martin H. Jr.4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)
- INSIDERSEC Form 4 filed by Director Fletcher Aaron G.L.4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)
- SECSEC Form S-8 filed by Actuate Therapeutics Inc.S-8 - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)
- SECSEC Form 10-Q filed by Actuate Therapeutics Inc.10-Q - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)
- SECActuate Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)
- PRActuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development ProgramElraglusib oral tablet formulation to drive next-phase clinical development and broader clinical useFDA cleared IND for Phase 1/2 study of oral elraglusib in advanced cancer patients, with focus on metastatic melanoma, NSCLC, colorectal, and pancreatic cancers with initiation planned for 2H 2026Elraglusib plus RAS inhibitor preclinical results expected in mid-2026 Industry veteran Martin Huber, MD, joins Board of Directors CHICAGO and FORT WORTH, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers
- INSIDERSEC Form 3 filed by new insider Huber Martin H. Jr.3 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)
- SECSEC Form DEFA14A filed by Actuate Therapeutics Inc.DEFA14A - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)
- SECActuate Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits8-K - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)
- PRActuate Therapeutics Announces Key Appointment of Industry Veteran to Board of DirectorsCHICAGO and FORT WORTH, Texas, May 06, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers, today announced the appointment of Martin Huber, MD, as an Independent Director, effective immediately. This appointment strengthens Actuate's leadership team as it advances elraglusib across multiple difficult-to-treat cancer indications toward registration studies and commercialization. "We are pleased to welcome Marty to our Board of Directors. His dedication and expertise are going to prove invaluable to our mission,
- PRActuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal AdenocarcinomaMedian overall survival increased by >40% in elraglusib arm compared to the control arm, with a 1-year survival rate of 44% in the elraglusib arm versus 22% in the control arm 18-month survival rate >20% in elraglusib arm compared to 4% in control armConsistent survival benefit observed across the poorest prognosis patient subgroups, including those with liver metastases and high disease burden7-40X increases in tumor-infiltrating cytotoxic immune cells and biomarker signals in the elraglusib arm reflect immunomodulatory mechanisms of action CHICAGO and FORT WORTH, Texas, April 14, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-s
- SECSEC Form DEFA14A filed by Actuate Therapeutics Inc.DEFA14A - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)
- SECSEC Form DEF 14A filed by Actuate Therapeutics Inc.DEF 14A - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)
- INSIDERSEC Form 4 filed by Schmitt Daniel M4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)
- INSIDERSEC Form 4 filed by Mazar Andrew Paul4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)
- INSIDERSEC Form 4 filed by Lytle Paul J4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)
- SECSEC Form 10-K filed by Actuate Therapeutics Inc.10-K - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)
- NEWSActuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformative Combinations in RAS-Driven CancersMeg Flippin, Benzinga Staff WriterCHICAGO, IL AND FORT WORTH, TX / ACCESS Newswire / March 24, 2026 / Actuate Therapeutics, Inc. (NASDAQ:ACTU) is a clinical-stage biopharmaceutical company advancing elraglusib, a first-in-class, highly selective small-molecule inhibitor of glycogen synthase kinase-3 beta (GSK-3β). This multimodal agent targets tumor survival pathways, DNA damage response, NF-κB signaling and the tumor immune microenvironment, offering a new potential treatment across multiple difficult-to-treat cancers including metastatic pancreatic ductal adenocarcinoma (mPDAC), melanoma, colorectal cancer and sarcomas.What sets Actuate apart is its dual formulation strategy and recent mom
ACTU FAQ
6 questionsWhere does ACTU stock trade?
Actuate Therapeutics Inc. (ACTU) is listed on NASDAQ.What sector and industry is ACTU in?
Actuate Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Actuate Therapeutics Inc. go public?
Actuate Therapeutics Inc. (ACTU) completed its IPO in 2024.What are analysts saying about ACTU?
Actuate Therapeutics Inc. has had 3 recent analyst actions on file. The most recent action was from B. Riley Securities: Buy with a $2000.00 price target on 2025-08-26. Recent price targets range from $2000.00 to $2100.00.What companies are similar to ACTU?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ACTU side-by-side with any of them on Quantisnow.How can I track ACTU on Quantisnow?
Quantisnow aggregates Actuate Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ACTU to receive live email and push alerts on every new disclosure.